Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy

INTRODUCTION: Drotrecogin alfa (activated) (DrotAA) is licensed in the United States and the European Union for the treatment of severe sepsis with multiple organ failure. Patients with severe sepsis on renal replacement therapy (RRT), who typically receive additional anticoagulation to prevent circ...

Descripción completa

Detalles Bibliográficos
Autores principales: Camporota, Luigi, Corno, Eleonora, Menaldo, Eleonora, Smith, John, Lei, Katie, Beale, Richard, Wyncoll, Duncan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646328/
https://www.ncbi.nlm.nih.gov/pubmed/19094233
http://dx.doi.org/10.1186/cc7163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646328/
https://www.ncbi.nlm.nih.gov/pubmed/19094233
http://dx.doi.org/10.1186/cc7163

Ejemplares similares